Singapore, Jan 11th, 2024:
Breathonix Pte Ltd (“Breathonix”), a leader in non-invasive breath analysis technology, today announced a collaborative study with the University of Oklahoma (OU) published in Open Access Government – ‘Revolutionizing Disease Detection: The Emergence of Non-Invasive VOC Breathomics.’
The study addresses the urgent need for rapid, accurate, and non-invasive diagnostic methods highlighted by the COVID-19 pandemic, and other respiratory diseases like RSV and flu. Breathomics analyzes volatile organic compounds (VOCs) in exhaled breath to detect diseases, offering a promising solution.
Historically, Breathomics has evolved with advancements like Proton Transfer Reaction – Mass Spectrometry (PTR-MS), enabling the detection of around 3,000 VOCs.
This collaboration, supported by NSF funding, aims to develop rapid, point-of-care breath tests for pandemic preparedness. OU’s health science center and Data Institute for Societal Challenges bring expertise in clinical research and AI and machine learning for precise diagnostics, an Breathonix brings expertise in rapid and point-of-care breath analysis
Breathomics represents a significant leap in medical diagnostics, providing swift, accurate detection of diseases, enhancing early intervention and treatment. This collaboration between Breathonix and OU exemplifies the potential of Breathomics to transform global health outcomes.
For more details about this study, read https://doi.org/10.56367/OAG-041-10923